Thông tin thuốc gốc
Chỉ định và Liều dùng
Adult: As conventional tab: 1.25-2.5 mg once daily. As modified release tab: 1.5 mg once daily.

Adult: Initially, 2.5 mg once daily. May increase to 5 mg daily after 1 week if necessary.
Cách dùng
May be taken with or without food.
Chống chỉ định
Hypersensitivity to sulfonamide-derived drugs. Anuria; severe renal failure, hepatic encephalopathy, severe impairment of liver function, hypokalaemia.
Thận trọng
Patient with electrolyte or fluid disturbances, gout, diabetes mellitus, Addison’s disease, SLE. Renal and hepatic impairment. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Photosensitivity, hypersensitivity reactions, electrolyte imbalance (e.g. hyponatraemia, hypokalaemia, hypochloremic alkalosis, hypomagnesaemia, hypercalcaemia).
Cardiac disorders: Arrhythmia, chest pain, palpitations.
Eye disorders: Blurred vision, conjunctivitis.
Gastrointestinal disorders: Constipation, diarrhoea, dyspepsia, abdominal pain, dry mouth, nausea, vomiting.
General disorders and administration site conditions: Fatigue, lethargy, malaise.
Investigations: Increased blood glucose, increased blood uric acid, elevated liver enzyme levels.
Musculoskeletal and connective tissue disorders: Muscle cramps, muscle spasms, back pain.
Nervous system disorders: Dizziness, headache, paresthesia, vertigo.
Psychiatric disorders: Insomnia.
Renal and urinary disorders: Nocturia, polyuria.
Respiratory, thoracic and mediastinal disorders: Rhinitis, cough, pharyngitis, rhimorrhea, sinusitis.
Skin and subcutaneous tissue disorders: Pruritus, maculopapular rash, urticaria.
Thông tin tư vấn bệnh nhân
This medicine may cause photosensitivity reactions, avoid exposure to direct sunlight and UV light. Use protective measures (e.g. applying sunscreen) when going outdoors.
Chỉ số theo dõi
Monitor blood pressure, serum electrolytes, uric acid, renal and hepatic function. Assess weight, intake and output reports daily to determine fluid loss.
Quá liều
Symptoms: Nausea, vomiting, weakness, gastrointestinal disorders, electrolyte depletion (e.g. hyponatraemia, hypokalaemia), hypotension, cramps, vertigo, drowsiness, confusion, polyuria or oliguria leading to anuria. Management: Symptomatic and supportive treatment. May induce emesis or perform gastric lavage. Administration of activated charcoal may be done within 1-2 hours after ingestion. Correct electrolyte and fluid imbalance as necessary.
Tương tác
Increased risk of lithium toxicity. Increased risk of hypokalaemia and ventricular arrhythmia with drugs that induce torsades de pointes (e.g. disopyramide, amiodarone, sotalol, chlorpromazine, amisulpride, haloperidol). May enhance toxicity of cardiac glycosides (e.g. digoxin). Diminished antihypertensive effect with NSAIDs. May potentiate the action of other antihypertensive agents.
Tương tác với thức ăn
Potentiated orthostatic hypotension with alcohol.
Ảnh hưởng đến kết quả xét nghiệm
May interfere with parathyroid function tests. May cause false positive result to aldosterone/renin ratio (AAR).
Tác dụng
Mechanism of Action: Indapamide, a diuretic with similar effects as thiazides, enhances excretion of sodium, chloride and water by interfering with the transport of sodium ions across the renal tubular epithelium.
Absorption: Rapidly and completely absorbed from the gastrointestinal tract. Bioavailability: 93%. Time to peak plasma concentration: 2 hours.
Distribution: Widely distributed into the body tissues. Volume of distribution: 25 L. Plasma protein binding: 71-79%.
Metabolism: Extensively metabolised in the liver.
Excretion: Mainly via the urine (approx 70%; 7% as unchanged drug); faeces (16-23%). Elimination half-life: Approx 14 hours.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 3702, Indapamide. Accessed Sept. 24, 2020.

Bảo quản
Store between 20-25°C.
Phân loại MIMS
Thuốc lợi tiểu
Phân loại ATC
C03BA11 - indapamide ; Belongs to the class of low-ceiling sulfonamide diuretics.
Tài liệu tham khảo
Anon. Indapamide. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 17/07/2020.

Anon. Indapamide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 17/07/2020.

Buckingham R (ed). Indapamide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 17/07/2020.

Indapamide Tablet (ANI Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 17/07/2020.

Joint Formulary Committee. Indapamide. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 17/07/2020.

Natrilix SR Film-Coated Tablets (Servier Laboratories Aust. Pty Ltd). MHRA. Accessed 17/07/2020.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Indapamide từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Apo-Indapamide
  • Dapa-tabs
  • Fludex
  • Indapa SR
  • Indapamide JSC
  • Indapen
  • Indatab SR/Lorvas
  • Inpalix
  • Natrilix SR
  • Pamidstad
  • Rinalix-Xepa
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in